“Global tissue diagnostics market is expected to reach $8.24 Bn by 2029”, says Visiongain

08 January 2020
Pharma

Visiongain’s new report the Tissue Diagnostics Market Report 2019-2029: Forecasts by Product (Consumables, Instruments), by Product (Immunohistochemistry, in Situ Hybridization, Digital Pathology, Others), by Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-Small Cell Lung Cancer, Others), by End User (Hospitals, Research Labs, Pharmaceutical Companies, Research Organizations), plus analysis of leading companies operating in the global tissue diagnostics market.

In 2019, the global tissue diagnostics market was valued at $4.09 billion and is expected to reach $8.24 billion by 2029 at a CAGR of 7.2% over the forecast period. Rising cancer prevalence all over the world, expanding healthcare infrastructure in developing countries, growing healthcare diagnostics affordability, technological advancement in imaging, and growth in personalized therapeutics is expected to increase tissue diagnostics market expansion over the projected period.

Improving healthcare infrastructure in developing countries such as India, China, Indonesia, Singapore, Malaysia, South Korea, Brazil, and Colombia is expected to encourage healthcare service providers to expand their facilities in these countries. Additionally, increasing disposable income followed by increasing healthcare spending has increased market penetration of tissue diagnostics over the past few years and the trend is expected to continue over the course of time.

Technological advancement in tissue diagnostics is expected to open avenues in the global healthcare industry. For instance, in 2018, According to University of Illinois, a new microscope system can image living tissue in real time and in molecular detail, without any chemicals or dyes. Some other prominent technologies innovated in 2017 are a Mass Spec Pen To Rapidly Identify Cancer, Paper Point-of-Care Zika Test, Transparent Tissues for Pathological Diagnosis, Paper-based Electrochemical Diagnostics, Microfluidic Chip to Predict Preterm Birth, Smartphone TRI Analyzer, and Wearable Sweat Sensor.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever